Cargando…

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is an effective form of treatment for patients with metastatic neuroendocrine tumors (NETs). However, delivering sufficient radiation dose to the tumor to result in a high percentage of long-term tumor remissions remains challenging because of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bushnell, David L, Madsen, Mark T, O’cdorisio, Thomas, Menda, Yusuf, Muzahir, Saima, Ryan, Randi, O’dorisio, M Sue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452658/ https://www.ncbi.nlm.nih.gov/pubmed/26116109 http://dx.doi.org/10.1186/s13550-014-0038-2

Ejemplares similares

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Prospective Analysis of the Impact of (68)Ga-DOTATOC Positron Emission Tomography–Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors
por: Ghobrial, Silvia N., et al.
Publicado: (2020)

Gastroenteropancreatic neuroendocrine tumors in children and young adults
por: Khanna, Geetika, et al.
Publicado: (2007)

Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience
por: Verma, Priyanka, et al.
Publicado: (2012)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
por: Jodrell, D. I., et al.
Publicado: (1988)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

I-131 mIBG Scintigraphy Curie Versus SIOPEN Scoring: Prognostic Value in Stage 4 Neuroblastoma
por: Riaz, Saima, et al.
Publicado: (2018)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

The Vital Role of (131) I-MIBG in Localization of Paraganglioma at Unusual Sites
por: Singhal, Tejasvini, et al.
Publicado: (2022)

EANM Dosimetry Committee series on standard operational procedures for internal dosimetry for (131)I mIBG treatment of neuroendocrine tumours
por: Gear, Jonathan, et al.
Publicado: (2020)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity
por: Vinjamuri, S, et al.
Publicado: (2013)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Individualized (131)I-mIBG therapy in the management of refractory and relapsed neuroblastoma
por: George, Sally L., et al.
Publicado: (2016)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

(90)Y/(177)Lu-DOTATOC: From Preclinical Studies to Application in Humans
por: Uccelli, Licia, et al.
Publicado: (2021)

SUN-LB26 Radioligand Theranostics of Endocrine-Related Cancers; A New, Revolutionary Approach
por: Harris, Alan G, et al.
Publicado: (2020)

Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues
por: Anthony, Lowell B., et al.
Publicado: (2021)

Staging of neuroendocrine tumours: comparison of [(68)Ga]DOTATOC multiphase PET/CT and whole-body MRI
por: Schraml, C., et al.
Publicado: (2013)

Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT
por: Treglia, Giorgio, et al.
Publicado: (2013)

Repeated Radionuclide therapy in metastatic paraganglioma leading to the highest reported cumulative activity of (131)I-MIBG
por: Ezziddin, Samer, et al.
Publicado: (2012)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Nothing but NET: A review of norepinephrine transporter expression and efficacy of (131)I-mIBG therapy
por: Streby, Keri A, et al.
Publicado: (2015)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Growing vascular endothelial cells express somatostatin subtype 2 receptors
por: Watson, J C, et al.
Publicado: (2001)

Commissioning of the 131/90 lattice
por: Lamont, M, et al.
Publicado: (1998)

The therapeutic efficacy of (177)Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis
por: Wang, Li-fan, et al.
Publicado: (2020)

Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2013)

Metastatic Pheochromocytoma Diagnosed with (131) I-MIBG SPECT/CT Imaging in a Patient with Pathogenic VHL Mutation
por: Vankadari, Kousik, et al.
Publicado: (2022)

Auranofin Inhibition of Thioredoxin Reductase in a Preclinical Model of Small Cell Lung Cancer
por: Johnson, Spenser S., et al.
Publicado: (2023)

MON-202 Germline SDHB Exon 1 Deletion Is Associated with Absence of (131)I-metaiodobenzylguanidine (MIBG) Uptake in Malignant Paragangliomas
por: Petenuci, Janaina, et al.
Publicado: (2020)

Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with (90)Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI
por: Weikert, Thomas, et al.
Publicado: (2019)

Unusual Presentation of Bladder Paraganglioma: Comparison of (131)I MIBG SPECT/CT and (68)Ga DOTANOC PET/CT
por: Jain, Tarun Kumar, et al.
Publicado: (2016)

(68)Ga-DOTATATE PET/CT Compared with (131)I-MIBG SPECT/CT in the Evaluation of Neural Crest Tumors
por: Shahrokhi, Pezhman, et al.
Publicado: (2020)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

The current status of somatostatin receptors in malignant melanoma.
por: Fletcher, W. S., et al.
Publicado: (1997)

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy
por: Tran, Catherine G., et al.
Publicado: (2022)

Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy
por: Mastrangelo, S, et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_l0sa046nfqgnv37d1jaq2053tq